Lu et al. [60] evaluate the cost-effectiveness of the ALK tests followed by crizotinib compared to the standard chemotherapy in advanced NSCLC from the Chinese healthcare system perspective. The gene discussed is ALK; the disease is non-small cell lung carcinoma.